Revolution Medicines (RVMD) EBITDA (2019 - 2026)
Revolution Medicines' quarterly EBITDA came in at -$445.2 million in Q1 2026, down 84.92% year-on-year from -$3.0 billion in Q1 2025, and down 22.06% quarter-over-quarter from -$364.8 million in Q4 2025.
Revolution Medicines has reported EBITDA for 8 years, with the latest figure at -$445.2 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 84.92% year-over-year to -$445.2 million; the trailing twelve-month figure through Mar 2026 stood at -$1.4 billion (down 84.96% YoY), and the FY2025 full-year result was -$1.1 billion, down 88.45% from the prior year.
- EBITDA for Q1 2026 stood at -$445.2 million, down from -$364.8 million in the prior quarter.
- The five-year high for EBITDA was -$57.9 million in Q1 2022, with the low at -$445.2 million in Q1 2026.
- Average EBITDA over 5 years is -$175.0 million, with a median of -$150.6 million recorded in 2024.
- Year-over-year, EBITDA decreased 16.62% in 2022 and plunged 159.49% in 2023.
- Tracing RVMD's EBITDA over 5 years: stood at -$61.7 million in 2022, then sank by 159.49% to -$160.1 million in 2023, then slipped by 23.07% to -$197.1 million in 2024, then slumped by 85.11% to -$364.8 million in 2025, then declined by 22.06% to -$445.2 million in 2026.
- The last three EBITDA figures came in at -$445.2 million (Q1 2026), -$364.8 million (Q4 2025), and -$303.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Revolution Medicines | 31.20 Bn | 31.20 Bn | - | -445.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -445.22 Mn |
| Dec 31, 2025 | -364.77 Mn |
| Sep 30, 2025 | -303.39 Mn |
| Jun 30, 2025 | -264.71 Mn |
| Mar 31, 2025 | -240.76 Mn |
| Dec 31, 2024 | -197.06 Mn |
| Sep 30, 2024 | -150.61 Mn |
| Jun 30, 2024 | -156.64 Mn |
| Mar 31, 2024 | -140.86 Mn |
| Dec 31, 2023 | -160.12 Mn |
| Sep 30, 2023 | -108.05 Mn |
| Jun 30, 2023 | -108.80 Mn |
| Mar 31, 2023 | -75.16 Mn |
| Dec 31, 2022 | -61.71 Mn |
| Sep 30, 2022 | -76.53 Mn |
| Jun 30, 2022 | -62.09 Mn |
| Mar 31, 2022 | -57.95 Mn |
| Dec 31, 2021 | -52.91 Mn |
| Sep 30, 2021 | -53.16 Mn |
| Jun 30, 2021 | -44.54 Mn |
| Mar 31, 2021 | -37.40 Mn |
| Dec 31, 2020 | -34.08 Mn |
| Sep 30, 2020 | -27.55 Mn |
| Jun 30, 2020 | -27.98 Mn |
| Mar 31, 2020 | -21.08 Mn |
| Dec 31, 2019 | -19.56 Mn |
| Sep 30, 2019 | -13.56 Mn |
| Jun 30, 2019 | -10.56 Mn |
| Mar 31, 2019 | -10.44 Mn |